samedan logo
 
 
 
spacer
home > ebr > winter 2001 > real options evaluation in pharmaceutical r&d: a new approach to financial project evaluation
PUBLICATIONS
European Biopharmaceutical Review

Real Options Evaluation in Pharmaceutical R&D: A New Approach to Financial Project Evaluation

The financial literature relating to options is daunting, both because of its volume and, in large part, its technical nature - the latter only rendered more obscure by the associated jargon. For those courageous enough to wade into the depths of this literature, frustration will be experienced both in extracting information relevant to pharmaceutical R&D and, even more so, in applying it. Thus, Dr Kerstin M. Bode-Greuel (the author of this report) is unusually well-equipped to act as a guide through the wilderness for the following reasons:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
A Review by Dr Roy Drucker, General Manager at Technomark Consulting Services Ltd

Roy Drucker joined the European R&D arm of Sterling Drug Inc as a Medical Advisor. He was promoted to being responsible for clinical pharmacology, drug metabolism and bioanalysis in Europe. In 1986 he moved to the Upjohn Company, subsequently Pharmacia & Upjohn, Inc., where he held a range of international responsibilities. His positions there included Director of Marketing with responsibility for worldwide marketing of cardiovascular products; Executive Director, European Community Affairs and Business Systems; and Vice-President, Drug Development, with global responsibility in multiple therapeutic areas for clinical drug development and medical support for marketed products.
A graduate of the Harvard Business School Advanced Management Program, Member of the Securities Institute and an FSA registered Approved Person, Roy has been based in Belgium, the UK, and the US. Roy has been General Manager of Technomark since September 1996.

spacer
Roy Drucker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement